Takara Bio Europe, a wholly owned subsidiary of Takara Bio Inc., announces the launch of the Shasta™ Single-Cell System at the 2024 Human Cell Atlas General Meeting. This cutting-edge, high-throughput NGS solution enables novel biomarker discovery in oncology research. This comprehensive system combines well-validated chemistries with user-friendly bioinformatics tools, allowing researchers to mine more genomic and transcriptomic information from a much greater number of cells than previously possible, all while reducing both time and costs.

Unrivalled throughput
The Shasta system and Shasta Whole-Genome Amplification (WGA) Kit dramatically increase throughput for WGA by processing up to 1,500 cells per run, while current technologies are limited to 384 single cells, and enable the detection of single-cell level CNV events via shallow sequencing. The Shasta Total RNA-Seq Kit is the first high-throughput single-cell total RNA profiling kit to offer full gene body coverage of up to 100,000 cells per run. It is capable of detecting RNA biotypes, such as non-polyadenylated lncRNAs, otherwise missed by current droplet-based technologies. This represents a significant advancement over traditional plate-based full-length RNA-seq and high-throughput mRNA-seq methods.

“We have entered a new era in single-cell analysis, where Shasta technologies overcome previous limitations, enabling detection of critical events such as splicing isoforms, gene fusions, lncRNAs, and segmental CNVs. By enabling true biomarker discovery at scale, we are providing researchers with the confidence and capability to achieve insights that were previously out of reach,” said Matthieu Pesant, PhD, Senior Market Strategy Manager for Translational Genomics at Takara Bio Europe.


“I’m thrilled to share how Shasta Single-Cell System is set to revolutionise single-cell omics. Stop by our booth or join my talk to see first-hand how this technology can transform your research by detecting critical genetic events with unmatched throughput and sensitivity,” said Dr. Pesant.